Brooklyn ImmunoTherapeutics Inc logo

BTX

Brooklyn ImmunoTherapeutics Inc

$0.54

Earnings Summary

Net Profits
$-9.38Mn

Highlights

Net Profits:

Brooklyn ImmunoTherapeutics Inc’s net profit jumped 7.04% since last year same period to $-9.38Mn in the Q2 2022. On a quarterly growth basis, Brooklyn ImmunoTherapeutics Inc has generated -10.67% fall in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Brooklyn ImmunoTherapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.14
EPS Estimate Current Year
-0.14

Highlights

EPS Estimate Current Quarter:

Brooklyn ImmunoTherapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.14 - a -16.67% fall from last quarter’s estimates.

EPS Estimate Current Year:

Brooklyn ImmunoTherapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.14.

Key Ratios

Key ratios of the Brooklyn ImmunoTherapeutics Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-0.17
Return on Assets (ROA)
-0.35
Return on Equity (ROE)
-4.27
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Brooklyn ImmunoTherapeutics Inc’s earning per share (EPS) jumped 29.17% since last year same period to -0.17 in the Q2 2022. This indicates that the Brooklyn ImmunoTherapeutics Inc has generated 29.17% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Brooklyn ImmunoTherapeutics Inc’s return on assets (ROA) stands at -0.35.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Brooklyn ImmunoTherapeutics Inc’s return on equity (ROE) stands at -4.27.

Dividend Per Share (DPS):

Brooklyn ImmunoTherapeutics Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-07-01
-0.14
-0.17
-21.43%
2022-04-15
-0.12
-0.16
-33.33%

Company Information

Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance therapies using leading edge gene editing/cell therapy technology through its option agreements with Factor Bioscience and Novellus. Brooklyn’s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.

Organisation
Brooklyn ImmunoTherapeutics Inc
Employees
2.02K
Industry
Health Technology